Stem definition | Drug id | CAS RN |
---|---|---|
opioid receptor agonists, analgesics, fentanyl derivatives | 2363 | 132875-61-7 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
Vd (Volume of distribution) | 0.40 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 37 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.30 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 12, 1996 | FDA | MYLAN INSTITUTIONAL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 679.25 | 30.56 | 178 | 3560 | 19977 | 50581409 |
Anaphylactic reaction | 311.45 | 30.56 | 125 | 3613 | 53930 | 50547456 |
Cardiac arrest | 124.10 | 30.56 | 77 | 3661 | 83574 | 50517812 |
Bronchospasm | 123.48 | 30.56 | 45 | 3693 | 14809 | 50586577 |
Delayed recovery from anaesthesia | 115.82 | 30.56 | 23 | 3715 | 726 | 50600660 |
Circulatory collapse | 103.66 | 30.56 | 43 | 3695 | 19957 | 50581429 |
Hypotension | 89.70 | 30.56 | 98 | 3640 | 235371 | 50366015 |
Bradycardia | 84.70 | 30.56 | 55 | 3683 | 64371 | 50537015 |
Neuromuscular block prolonged | 80.86 | 30.56 | 16 | 3722 | 495 | 50600891 |
Hyperthermia malignant | 74.98 | 30.56 | 16 | 3722 | 723 | 50600663 |
Tachycardia | 73.57 | 30.56 | 60 | 3678 | 99703 | 50501683 |
Serotonin syndrome | 70.35 | 30.56 | 35 | 3703 | 24678 | 50576708 |
Blood pressure decreased | 64.45 | 30.56 | 44 | 3694 | 55865 | 50545521 |
Stress cardiomyopathy | 54.92 | 30.56 | 21 | 3717 | 7866 | 50593520 |
Anaphylactoid reaction | 54.91 | 30.56 | 17 | 3721 | 3389 | 50597997 |
Patent ductus arteriosus | 52.99 | 30.56 | 17 | 3721 | 3803 | 50597583 |
Exposure during pregnancy | 52.34 | 30.56 | 54 | 3684 | 120961 | 50480425 |
Anaphylactoid shock | 50.58 | 30.56 | 10 | 3728 | 308 | 50601078 |
Pulseless electrical activity | 46.86 | 30.56 | 18 | 3720 | 6823 | 50594563 |
Hyperreflexia | 44.34 | 30.56 | 16 | 3722 | 5102 | 50596284 |
Clonus | 43.60 | 30.56 | 15 | 3723 | 4160 | 50597226 |
Premature baby | 40.74 | 30.56 | 22 | 3716 | 18315 | 50583071 |
Dyskinesia | 39.56 | 30.56 | 25 | 3713 | 27836 | 50573550 |
Diabetes insipidus | 38.95 | 30.56 | 12 | 3726 | 2352 | 50599034 |
Toxic epidermal necrolysis | 35.33 | 30.56 | 21 | 3717 | 20971 | 50580415 |
Drug interaction | 33.70 | 30.56 | 56 | 3682 | 199565 | 50401821 |
Subcutaneous emphysema | 31.77 | 30.56 | 8 | 3730 | 749 | 50600637 |
Fatigue | 31.47 | 30.56 | 7 | 3731 | 707594 | 49893792 |
Trigemino-cardiac reflex | 30.58 | 30.56 | 5 | 3733 | 50 | 50601336 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 499.38 | 31.67 | 143 | 3519 | 13193 | 29557672 |
Anaphylactic reaction | 212.22 | 31.67 | 91 | 3571 | 27482 | 29543383 |
Cardiac arrest | 143.01 | 31.67 | 103 | 3559 | 85488 | 29485377 |
Hypotension | 109.79 | 31.67 | 127 | 3535 | 194227 | 29376638 |
Hyperthermia malignant | 107.91 | 31.67 | 28 | 3634 | 1756 | 29569109 |
Delayed recovery from anaesthesia | 104.78 | 31.67 | 23 | 3639 | 700 | 29570165 |
Neuromuscular block prolonged | 103.09 | 31.67 | 21 | 3641 | 442 | 29570423 |
Trigemino-cardiac reflex | 89.37 | 31.67 | 16 | 3646 | 163 | 29570702 |
Propofol infusion syndrome | 86.14 | 31.67 | 20 | 3642 | 787 | 29570078 |
Bradycardia | 82.95 | 31.67 | 67 | 3595 | 65562 | 29505303 |
Blood pressure decreased | 76.31 | 31.67 | 55 | 3607 | 45422 | 29525443 |
Bronchospasm | 74.66 | 31.67 | 32 | 3630 | 9577 | 29561288 |
Airway complication of anaesthesia | 72.12 | 31.67 | 13 | 3649 | 138 | 29570727 |
Toxic epidermal necrolysis | 69.05 | 31.67 | 37 | 3625 | 18116 | 29552749 |
Drug interaction | 66.12 | 31.67 | 100 | 3562 | 197285 | 29373580 |
Ventricular fibrillation | 59.45 | 31.67 | 32 | 3630 | 15801 | 29555064 |
Hypoventilation | 57.19 | 31.67 | 19 | 3643 | 2822 | 29568043 |
Kounis syndrome | 56.68 | 31.67 | 17 | 3645 | 1812 | 29569053 |
Diabetes insipidus | 55.96 | 31.67 | 18 | 3644 | 2416 | 29568449 |
Seizure like phenomena | 53.69 | 31.67 | 13 | 3649 | 613 | 29570252 |
Drug reaction with eosinophilia and systemic symptoms | 47.23 | 31.67 | 34 | 3628 | 27958 | 29542907 |
Arteriospasm coronary | 47.06 | 31.67 | 16 | 3646 | 2549 | 29568316 |
Circulatory collapse | 46.75 | 31.67 | 29 | 3633 | 18644 | 29552221 |
Recurrence of neuromuscular blockade | 41.22 | 31.67 | 8 | 3654 | 130 | 29570735 |
Cardio-respiratory arrest | 40.57 | 31.67 | 40 | 3622 | 50561 | 29520304 |
Erythema | 40.03 | 31.67 | 48 | 3614 | 75558 | 29495307 |
Anaesthetic complication neurological | 39.74 | 31.67 | 9 | 3653 | 316 | 29570549 |
Sinus arrest | 38.65 | 31.67 | 12 | 3650 | 1435 | 29569430 |
Anaphylactoid shock | 38.58 | 31.67 | 9 | 3653 | 361 | 29570504 |
Status epilepticus | 38.23 | 31.67 | 21 | 3641 | 10773 | 29560092 |
Rhabdomyolysis | 36.17 | 31.67 | 41 | 3621 | 60767 | 29510098 |
Anaphylactoid reaction | 35.16 | 31.67 | 12 | 3650 | 1933 | 29568932 |
Tachycardia | 35.13 | 31.67 | 44 | 3618 | 72366 | 29498499 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 1132.77 | 26.86 | 319 | 7078 | 30009 | 64461326 |
Anaphylactic reaction | 513.49 | 26.86 | 217 | 7180 | 68447 | 64422888 |
Cardiac arrest | 245.63 | 26.86 | 175 | 7222 | 153889 | 64337446 |
Delayed recovery from anaesthesia | 204.98 | 26.86 | 45 | 7352 | 1483 | 64489852 |
Bronchospasm | 179.93 | 26.86 | 74 | 7323 | 21608 | 64469727 |
Hypotension | 176.54 | 26.86 | 217 | 7180 | 380757 | 64110578 |
Neuromuscular block prolonged | 166.24 | 26.86 | 35 | 7362 | 942 | 64490393 |
Hyperthermia malignant | 158.58 | 26.86 | 40 | 7357 | 2419 | 64488916 |
Bradycardia | 138.71 | 26.86 | 112 | 7285 | 118107 | 64373228 |
Circulatory collapse | 136.86 | 26.86 | 70 | 7327 | 33662 | 64457673 |
Blood pressure decreased | 128.07 | 26.86 | 94 | 7303 | 86105 | 64405230 |
Trigemino-cardiac reflex | 118.09 | 26.86 | 21 | 7376 | 223 | 64491112 |
Tachycardia | 95.69 | 26.86 | 101 | 7296 | 149478 | 64341857 |
Propofol infusion syndrome | 92.94 | 26.86 | 24 | 7373 | 1593 | 64489742 |
Diabetes insipidus | 92.32 | 26.86 | 30 | 7367 | 4491 | 64486844 |
Airway complication of anaesthesia | 89.04 | 26.86 | 18 | 7379 | 394 | 64490941 |
Toxic epidermal necrolysis | 87.55 | 26.86 | 54 | 7343 | 37112 | 64454223 |
Anaphylactoid reaction | 86.94 | 26.86 | 29 | 7368 | 4709 | 64486626 |
Drug interaction | 86.28 | 26.86 | 151 | 7246 | 361932 | 64129403 |
Anaphylactoid shock | 83.57 | 26.86 | 19 | 7378 | 735 | 64490600 |
Ventricular fibrillation | 72.82 | 26.86 | 41 | 7356 | 23819 | 64467516 |
Recurrence of neuromuscular blockade | 69.20 | 26.86 | 13 | 7384 | 191 | 64491144 |
Hypoventilation | 69.14 | 26.86 | 26 | 7371 | 5980 | 64485355 |
Kounis syndrome | 65.54 | 26.86 | 21 | 7376 | 3004 | 64488331 |
Pulseless electrical activity | 65.22 | 26.86 | 31 | 7366 | 12708 | 64478627 |
Erythema | 63.73 | 26.86 | 92 | 7305 | 186978 | 64304357 |
Serotonin syndrome | 60.89 | 26.86 | 44 | 7353 | 39238 | 64452097 |
Stress cardiomyopathy | 58.26 | 26.86 | 26 | 7371 | 9231 | 64482104 |
Fatigue | 56.97 | 26.86 | 9 | 7388 | 748721 | 63742614 |
Rhabdomyolysis | 55.15 | 26.86 | 60 | 7337 | 91666 | 64399669 |
Post procedural complication | 52.75 | 26.86 | 32 | 7365 | 21321 | 64470014 |
Upper airway obstruction | 50.21 | 26.86 | 14 | 7383 | 1244 | 64490091 |
Respiratory depression | 47.54 | 26.86 | 31 | 7366 | 23412 | 64467923 |
Sinus arrest | 45.33 | 26.86 | 16 | 7381 | 3074 | 64488261 |
Seizure like phenomena | 42.17 | 26.86 | 13 | 7384 | 1639 | 64489696 |
Clonus | 41.27 | 26.86 | 18 | 7379 | 6049 | 64485286 |
Death | 41.03 | 26.86 | 4 | 7393 | 482701 | 64008634 |
Arteriospasm coronary | 39.75 | 26.86 | 17 | 7380 | 5448 | 64485887 |
Urticaria | 39.63 | 26.86 | 65 | 7332 | 147252 | 64344083 |
Pain | 39.12 | 26.86 | 8 | 7389 | 553503 | 63937832 |
Ventricular tachycardia | 39.09 | 26.86 | 32 | 7365 | 34233 | 64457102 |
Arthralgia | 36.71 | 26.86 | 4 | 7393 | 442256 | 64049079 |
Cardio-respiratory arrest | 35.82 | 26.86 | 50 | 7347 | 98343 | 64392992 |
Anaesthetic complication neurological | 35.80 | 26.86 | 9 | 7388 | 536 | 64490799 |
Nausea | 33.35 | 26.86 | 25 | 7372 | 785775 | 63705560 |
Anaesthetic complication | 32.74 | 26.86 | 12 | 7385 | 2567 | 64488768 |
Procedural hypotension | 32.44 | 26.86 | 11 | 7386 | 1875 | 64489460 |
Respiratory arrest | 32.42 | 26.86 | 35 | 7362 | 52950 | 64438385 |
Hyperreflexia | 32.38 | 26.86 | 16 | 7381 | 7132 | 64484203 |
Type I hypersensitivity | 32.36 | 26.86 | 13 | 7384 | 3561 | 64487774 |
Blood pressure immeasurable | 32.32 | 26.86 | 11 | 7386 | 1897 | 64489438 |
Drug reaction with eosinophilia and systemic symptoms | 31.75 | 26.86 | 35 | 7362 | 54182 | 64437153 |
Subcutaneous emphysema | 30.12 | 26.86 | 10 | 7387 | 1599 | 64489736 |
Fall | 29.47 | 26.86 | 6 | 7391 | 416820 | 64074515 |
Electrocardiogram ST segment elevation | 29.22 | 26.86 | 15 | 7382 | 7244 | 64484091 |
Capillary nail refill test abnormal | 28.67 | 26.86 | 5 | 7392 | 47 | 64491288 |
Oxygen saturation decreased | 28.41 | 26.86 | 47 | 7350 | 107129 | 64384206 |
Dyskinesia | 27.64 | 26.86 | 28 | 7369 | 39360 | 64451975 |
None
Source | Code | Description |
---|---|---|
ATC | N01AH06 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Opioid anesthetics |
MeSH PA | D000700 | Analgesics |
MeSH PA | D000701 | Analgesics, Opioid |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D009294 | Narcotics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:35482 | narcotic analgesic |
CHEBI has role | CHEBI:35717 | hypnotics |
CHEBI has role | CHEBI:38877 | intravenous anesthetics |
CHEBI has role | CHEBI:55322 | mu-opioid agonists |
FDA MoA | N0000175684 | Full Opioid Agonists |
FDA EPC | N0000175690 | Opioid Agonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Local anesthesia | indication | 386761002 | |
Acute postoperative pain | indication | 107401000119105 | |
Low blood pressure | contraindication | 45007003 | |
Bradycardia | contraindication | 48867003 | |
Decreased respiratory function | contraindication | 80954004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.07 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mu-type opioid receptor | GPCR | AGONIST | WOMBAT-PK | CHEMBL | |||||
Mu-type opioid receptor | GPCR | IC50 | 9.22 | CHEMBL |
ID | Source |
---|---|
4024040 | VUID |
N0000022045 | NUI |
D01177 | KEGG_DRUG |
132539-07-2 | SECONDARY_CAS_RN |
4020990 | VANDF |
4024040 | VANDF |
C0246631 | UMLSCUI |
CHEBI:8802 | CHEBI |
CHEMBL1005 | ChEMBL_ID |
DB00899 | DRUGBANK_ID |
CHEMBL1201120 | ChEMBL_ID |
D000077208 | MESH_DESCRIPTOR_UI |
60815 | PUBCHEM_CID |
7292 | IUPHAR_LIGAND_ID |
6924 | INN_ID |
P10582JYYK | UNII |
236540 | RXNORM |
181723 | MMSL |
186043 | MMSL |
5415 | MMSL |
d04034 | MMSL |
006250 | NDDF |
006251 | NDDF |
108376001 | SNOMEDCT_US |
108379008 | SNOMEDCT_US |
386839004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9391 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9392 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9393 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 27 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-723 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-723 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-724 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-725 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-198 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-912 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-913 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-914 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-505 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-506 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-507 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 27 sections |